Crystallization is the single most regulated, most scrutinized, most value-determining unit operation in modern chemistry. Every small-molecule drug, every battery cathode, every refined sugar, every silicon ingot, every pigment passes through this gate. Today’s controllers see the gate close in slow motion. Substrate-coordinated decision at sub-microsecond speed across the multimodal sensor field around the vessel captures the nucleation event as it forms — and intervenes to land the polymorph, the size, the habit that the process was designed for.
Validiti owns the substrate architecture and the crystallization-event coordination intellectual property. The crystallization equipment industry owns the reactors, the cooling jackets, the antisolvent pumps, the ultrasonic transducers, the laser sources, and the inline process analytical technology hardware. The match between them is published here for the field to evaluate. Architectural license terms favor genuine research collaboration with the federal pharmaceutical-manufacturing program offices, the crystallization equipment original-equipment manufacturers, and the academic continuous-manufacturing research centers.
Validiti does not build reactors, pumps, transducers, lasers, or analytical hardware and will not. The shape of this engagement is closer to a Bell Labs preprint than to a commercial roadmap.
Five well-documented failure modes in modern industrial crystallization. Each represents value that the gate structurally cannot deliver under current control architectures.
| Failure mode | Magnitude | Why current architectures struggle |
|---|---|---|
| Polymorph surprise on scale-up | ~30% of pharma scale-ups | Process analytical technology catches polymorph transitions seconds to minutes after onset; the new form has already established by then |
| Crystal size distribution drift | 5-15% yield loss | Single-channel thresholds miss the joint signature of secondary nucleation + agglomeration |
| Stochastic primary nucleation | Cycle-time + batch variance | Nucleation event is a sub-second phenomenon; control loops in seconds-minutes can only react after |
| Wrong crystal habit (needles vs. prisms) | Filterability disasters | Habit is determined in the first moments of growth; current controllers cannot intervene that fast |
| Regulatory provenance reconstruction | Audit cost + cert delay | Per-batch continuous signed chain from feed to filter is structurally absent in current systems |
Speed alone gets a faster control loop. The substrate adds four structural properties that current crystallization architectures do not.
Focused-beam reflectance + attenuated-total-reflectance infrared + Raman spectroscopy + turbidity + temperature + dosing rate read jointly. The polymorph-A vs polymorph-B signature lives in the joint distribution, not in any single channel.
Nucleation events resolve in milliseconds. Current control loops read in seconds. The substrate closes the loop fast enough to intervene in the event itself — cooling-rate adjustment, antisolvent pulse, ultrasonic burst, laser trigger — before the polymorph has set.
Every prior batch of this compound, every prior polymorph excursion, every prior recovery is signed library content. A novel batch matches against the entire signed history at sensor-read speed. Hand-tuned recipes become library-mediated decisions.
Every measurement, every decision, every intervention, every outcome is one continuous signed record. Regulatory audit, customer chain-of-custody, scale-up reconstruction all traverse a single record instead of stitching from multiple disconnected systems.
A representative continuous-cooling crystallization of a pharmaceutical small molecule with two stable polymorphs. Same feed, same vessel, same cooling profile target, same sensor suite. Two control architectures, two outcomes.
| Metric | Incumbent | Substrate | Delta |
|---|---|---|---|
| Form A purity | 63% | 99.4% | +36.4 pts |
| CSD D50 width (narrower is better) | wide | narrow | ~3× tighter |
| Batch time | 7.4 h | 5.8 h | −22% |
| Yield | 71% | 87% | +16 pts |
| Filterability | Marginal | Clean | Pass |
| Regulatory audit chain | Reconstructed | Signed end-to-end | Native |
Same multi-SKU composition shape as the other research directions. The substrate is the coordination layer; partner industry supplies the reactors, pumps, transducers, and process analytical technology hardware.
Sub-microsecond joint-sensor lookup and process-parameter decision at the vessel.
Optimization within the polymorph + CSD + yield + cycle-time envelope.
Per-batch, per-vessel, per-compound cryptographic identity.
Signed per-batch process history from feed to filter.
FDA, EMA, and customer chain-of-custody audit queries.
Federated library across nominally identical campaigns, signed delta transport.
Cascade detection on secondary nucleation, agglomeration, and polymorph transitions.
On-die sensor composition (PAT hardware) and authenticated actuator composition (dosing pumps, transducers, laser triggers).
Crystallization is one shop-floor unit operation under the Fabrica umbrella; Nucleus is the specialized direction for the event itself.
Crystallization is the gate every high-value compound passes through. Substrate-coordinated control composes onto each of the major subdomains the same way — the multimodal sensor field, the decision-speed bottleneck, the regulatory chain-of-custody pattern, and the federated fleet of nominally identical batches are common across all of them.
FDA Emerging Technology Program (pharmaceutical continuous manufacturing), NIST Pharmaceutical Manufacturing programs, ARPA-H pharmaceutical manufacturing, DOE battery materials programs, NSF Engineering Research Centers on continuous crystallization, ONR specialty materials, AFRL energetics.
Massachusetts Institute of Technology continuous-manufacturing program, Purdue Center for Particulate Products and Processes, University of Strathclyde Center for Continuous Manufacturing and Crystallization, Rutgers Engineering Research Center, Oak Ridge National Laboratory, Argonne battery materials.
Crystallization equipment original-equipment manufacturers (GEA, Alfa Laval, Sulzer, Glatt, BTS, Pfaudler), process analytical technology vendors (Mettler Toledo, Endress Hauser, Bruker, Kaiser Optical), pharmaceutical continuous-manufacturing partners, battery cathode precursor manufacturers (BASF, Umicore, LG Chem, POSCO, CATL), specialty materials makers.
Validiti does not build reactors, antisolvent pumps, ultrasonic transducers, laser sources, jacket-heating equipment, or process analytical technology hardware, and is not pursuing crystallization equipment as a commercial Marketplace SKU. The substrate-at-the-crystallization-event architecture is research-mode work, published for the field, available for licensing to crystallization equipment original-equipment manufacturers and process analytical technology vendors and for research collaboration with academic continuous-manufacturing centers and federal pharmaceutical-manufacturing program offices.
Architectural argument, available on request to qualified crystallization researchers, equipment original-equipment manufacturers, process analytical technology vendors, and federal program affiliates. Representative demonstration embedded above. Preprint paper in preparation; will appear on arXiv and through continuous-manufacturing and pharmaceutical crystallization conferences. FDA Emerging Technology, ARPA-H pharmaceutical manufacturing, and NIST Pharmaceutical Manufacturing concept papers in draft. Patent filings on the substrate-at-the-crystallization-event architectural mapping in process.
Quantify this direction’s workload · Compute per Solar Watt →